LY 233053

Discontinued Product

1521 has been discontinued.

View all NMDA Receptors products.
说明: Competitive NMDA antagonist
化学名: (2R*,4S*)-4-(1H-Tetrazol-5-ylmethyl)-2-piperidinecarboxylic acid
纯度: ≥99% (HPLC)
说明书
引用文献
评论
文献 (5)

生物活性 for LY 233053

LY 233053 is a competitive NMDA receptor antagonist (IC50 = 7 nM) that displays no affinity for AMPA or kainate receptors at a concentration of 10 μM. Inhibits NMDA-induced neuronal degeneration and protects from NMDA-induced convulsions in neonatal rats.

许可信息

Sold with the permission of Eli Lilly and Company

技术数据 for LY 233053

分子量 211.22
公式 C8H13N5O2
储存 Desiccate at RT
纯度 ≥99% (HPLC)
CAS Number 125546-04-5
PubChem ID 90479799
InChI Key RTVQJOXSBRCZBN-JUKSSJACSA-N
Smiles O=[C@@]([C@@H]1C[C@H](CC2=NN=NN2)CCN1)O.O=C([C@H]3C[C@@H](CC4=NN=NN4)CCN3)O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

参考文献 for LY 233053

参考文献是支持产品生物活性的出版物。

Schoepp et al (1990) Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-MthD.-aspartic acid antagonist with a short duration of action. J.Pharmacol.Exp.Ther. 255 1301 PMID: 2148188

Madden et al (1992) Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia. J.Neurosurg. 76 106 PMID: 1727148

Madden et al (1993) Delayed therapy of experimental ischemia with competitive N-MthD.-aspartate antagonists in rabbits. Stroke 24 1068 PMID: 8322381

按产品操作查看相关产品

查看全部 NMDA Receptor Antagonists

关键词: LY 233053, LY 233053 supplier, Competitive, NMDA, receptor, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, LY233053, 1521, Tocris Bioscience

篇 LY 233053 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 LY 233053 的引用文献。

LY 233053 的评论

目前没有该产品的评论。 Be the first to review LY 233053 and earn rewards!

Have you used LY 233053?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.